Opportunity Information: Apply for RFA AR 14 016
Apply for RFA AR 14 016
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Mar 21, 2014 and posted on Mar 21, 2014.
- Applicants must submit their applications by May 21, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Small businesses County governments City or township governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3)" (Funding Opportunity Number RFA-AR-14-016) is a National Institutes of Health (NIH) cooperative agreement aimed at building and supporting a coordinated research network focused on two major autoimmune diseases: rheumatoid arthritis (RA) and lupus. The central goal is to generate a clearer, systems-level picture of the biology driving these conditions by studying gene expression and cellular signaling in both diseased target tissues (from affected organs) and peripheral blood cells. By mapping out which biological pathways are shared between RA and lupus and which are disease-specific, the program is designed to help identify and prioritize promising drug targets, with the broader intent of speeding up the development of more effective therapies for autoimmune disease.
This opportunity sits within the broader Accelerating Medicines Partnership (AMP), a public-private effort meant to make biomedical research more collaborative and more directly useful for therapeutic development. In practical terms, the "Network Research Sites" component emphasizes assembling clinical and research sites capable of obtaining high-quality patient samples and associated clinical data, and then contributing those materials to a coordinated, standardized research pipeline. The FOA highlights enhanced systems biology, which generally means integrating multiple layers of biological information (for example, transcriptomics and signaling pathway activity) across different tissues and cell types to understand disease mechanisms in a more comprehensive way than single-measure studies typically allow.
The award mechanism is the UH2/UH3 phased cooperative agreement. This structure commonly supports a two-stage project: an initial UH2 phase that focuses on early milestones such as setting up operations, establishing workflows, and demonstrating feasibility, followed by a UH3 phase that supports expanded implementation once the initial requirements are met. Because it is a cooperative agreement rather than a standard grant, NIH is expected to have substantial programmatic involvement during the project, often including close coordination on milestones, data and sample standards, network governance, and overall project direction to keep the multi-site effort aligned.
The FOA is categorized as discretionary funding and falls under the NIH health research activity area. It is associated with CFDA numbers 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research), reflecting the cross-cutting nature of autoimmune disease research and the involvement of NIH institutes that focus on arthritis and immune-mediated disorders. There is no cost sharing or matching requirement listed, which means applicants are not required to provide non-federal matching funds as a condition of the award.
Eligibility is broad and includes a wide range of domestic and non-domestic organizations. Eligible applicants include nonprofit organizations (both 501(c)(3) and non-501(c)(3)), public and private institutions of higher education, public and state-controlled institutions of higher education, and a variety of government entities such as state, county, city/township, special district governments, independent school districts, and certain housing authorities. The FOA also allows applications from for-profit organizations (including small businesses and other for-profits), tribal governments (federally recognized and other than federally recognized), tribal organizations, and tribally controlled colleges and universities. It explicitly includes eligibility for several institution types that serve specific populations (for example, HBCUs, Hispanic-serving institutions, AANAPISI institutions, Alaska Native and Native Hawaiian-serving institutions), as well as faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and foreign organizations. This wide eligibility is consistent with a network model that may benefit from diverse clinical populations, specialized expertise, and geographically distributed recruitment and sampling capabilities.
Key administrative details include an original posted date of March 21, 2014, with an application closing date of May 21, 2014, and an archive date of June 21, 2014. The funding announcement is hosted through the NIH Grants Guide, with an additional information link provided in the source text. For technical difficulties accessing the announcement or linking to it, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
In summary, this FOA funded research sites within a larger AMP RA and Lupus Network, with the intent to standardize and scale the collection and analysis of patient-derived tissues and blood, produce integrated molecular and cellular datasets, and use those insights to clarify autoimmune disease pathways and accelerate identification of actionable drug targets.
Frequently Asked Questions (FAQs)
What is the official title of this grant opportunity?
The opportunity is titled "Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Research Sites (UH2/UH3)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-AR-14-016.
Which agency is offering this funding?
This is a National Institutes of Health (NIH) funding opportunity.
What type of award mechanism is used?
The mechanism is a UH2/UH3 phased cooperative agreement.
What does a "phased" UH2/UH3 cooperative agreement generally mean for a project?
The structure commonly supports two stages: an initial UH2 phase focused on early milestones (such as setting up operations, workflows, and feasibility), followed by a UH3 phase that supports expanded implementation after the initial requirements are met.
What does it mean that this is a cooperative agreement rather than a standard grant?
NIH is expected to have substantial programmatic involvement during the project. This often includes close coordination on milestones, standards for data and samples, network governance, and overall project direction so multiple sites stay aligned.
What is the primary purpose of this FOA?
The goal is to build and support a coordinated research network focused on rheumatoid arthritis (RA) and lupus to generate a clearer, systems-level picture of the biology driving these diseases and help identify and prioritize promising drug targets.
Which diseases are the focus of the network?
The network focuses on two autoimmune diseases: rheumatoid arthritis (RA) and lupus.
What kinds of biological information does the program aim to study?
The program emphasizes studying gene expression and cellular signaling in diseased target tissues (from affected organs) and in peripheral blood cells.
What is meant by "enhanced systems biology" in this context?
Enhanced systems biology generally refers to integrating multiple layers of biological information (for example, transcriptomics and signaling pathway activity) across different tissues and cell types to understand disease mechanisms more comprehensively than single-measure studies.
What types of samples are expected to be involved?
The FOA emphasizes obtaining high-quality patient samples and associated clinical data, including diseased target tissues (from affected organs) and peripheral blood cells, and contributing them to a coordinated and standardized research pipeline.
What is the intended outcome of comparing RA and lupus biology?
By mapping pathways that are shared between RA and lupus and those that are disease-specific, the program is designed to clarify autoimmune disease mechanisms and support identification and prioritization of actionable drug targets.
How does this opportunity relate to the broader Accelerating Medicines Partnership (AMP)?
This FOA sits within AMP, a public-private effort intended to make biomedical research more collaborative and more directly useful for therapeutic development.
What role do "Network Research Sites" play in the overall effort?
Network Research Sites are intended to be clinical and research sites capable of collecting high-quality patient samples and clinical data and contributing those materials to a coordinated, standardized pipeline used across the network.
Is this funding considered discretionary?
Yes. The FOA is categorized as discretionary funding.
What NIH activity area does this funding fall under?
It falls under NIH health research activities.
Which CFDA numbers are associated with this opportunity?
The FOA is associated with CFDA 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research), 93.855 (Allergy and Infectious Diseases Research), and 93.856 (Microbiology and Infectious Diseases Research).
Is cost sharing or matching required?
No cost sharing or matching requirement is listed. Applicants are not required to provide non-federal matching funds as a condition of the award.
Who is eligible to apply?
Eligibility is broad and includes domestic and non-domestic organizations, including nonprofits (501(c)(3) and non-501(c)(3)), public and private institutions of higher education, and a wide range of government entities.
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, including small businesses and other for-profit entities.
Are foreign (non-U.S.) organizations eligible?
Yes. The FOA indicates eligibility includes foreign organizations.
Are U.S. tribal entities eligible?
Yes. Eligible applicants include tribal governments (federally recognized and other than federally recognized), tribal organizations, and tribally controlled colleges and universities.
Are organizations in U.S. territories or possessions eligible?
Yes. The FOA explicitly includes U.S. territories or possessions among eligible applicants.
Are institutions serving specific populations explicitly included in eligibility?
Yes. The FOA explicitly includes institution types such as HBCUs, Hispanic-serving institutions, AANAPISI institutions, Alaska Native and Native Hawaiian-serving institutions, and similar organizations.
Are faith-based or community-based organizations eligible?
Yes. The FOA explicitly includes faith-based and community-based organizations.
What are the key dates for this FOA?
The original posted date is March 21, 2014. The application closing date is May 21, 2014. The archive date is June 21, 2014.
Where is the funding announcement hosted?
The announcement is hosted through the NIH Grants Guide, and the source text notes an additional information link.
Who should be contacted for technical difficulties accessing the announcement or links?
For technical difficulties, the listed contact is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What is the overall intended impact of the network?
The network is intended to standardize and scale the collection and analysis of patient-derived tissues and blood, produce integrated molecular and cellular datasets, clarify autoimmune disease pathways, and accelerate the identification of drug targets to support development of more effective therapies.
Browse more opportunities from the same category: Health
Next opportunity: Modeling Immunity for Biodefense (U19)
Previous opportunity: Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network Leadership Center (UM2)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AR 14 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AR 14 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Modeling Immunity for Biodefense (U19) Apply for RFA AI 14 028 Funding Number: RFA AI 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| CDCs National Undergraduate Student Program A Public Helath Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110104CONT14 Funding Number: CDC RFA MN11 110104CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas Apply for CDC RFA CK13 130102CONT14 Funding Number: CDC RFA CK13 130102CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Leveraging a Recovery Act Resource to Accelerate Research on Neurodevelopment (R01) Apply for RFA MH 15 400 Funding Number: RFA MH 15 400 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Provider Education and Public Awareness about Primary Immunodeficiency Disease Apply for CDC RFA OE12 120303CONT14 Funding Number: CDC RFA OE12 120303CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Targeting Latently Infected Cells Without Reactivation (R01) Apply for RFA AI 14 021 Funding Number: RFA AI 14 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Center for HIV, Viral Hepatitis, STD and TB Prevention (NCHHSTP) Apply for CDC RFA PS13 131502CONT14 Funding Number: CDC RFA PS13 131502CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIAID Division of Allergy, Immunology and Transplantation Statistical and Clinical Coordinating Center (UM2) Apply for RFA AI 14 016 Funding Number: RFA AI 14 016 Agency: National Institutes of Health Category: Health Funding Amount: $16,500,000 |
| National Environmental Medicine Education and Consultation Project (NEMECP) Apply for CDC RFA TS14 1401 Funding Number: CDC RFA TS14 1401 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Reduce Hepatitis Infections by Treatment and Integrated Prevention Services (Hepatitis TIPS) among Non urban Young Persons Who Inject Drugs Apply for RFA PS 14 004 Funding Number: RFA PS 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| National Diabetes Prevention Program Preventing Type 2 Diabetes Among People at High Risk Apply for CDC RFA DP12 121203CONT14 Funding Number: CDC RFA DP12 121203CONT14 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| High Impact Neuroscience Research Resource Grants (R24) Apply for RFA NS 14 006 Funding Number: RFA NS 14 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Studies of Mental Illness Not Involving Treatment Development, Efficacy, or Effectiveness Trials (Collaborative R01) Apply for PAR 14 165 Funding Number: PAR 14 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Area Competition Additional Area (SAC AA) Warrenton, GA Apply for HRSA 14 136 Funding Number: HRSA 14 136 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,185,045 |
| Biology of Manual Therapies (R21) Apply for PA 14 167 Funding Number: PA 14 167 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Biology of Manual Therapies (R01) Apply for PA 14 168 Funding Number: PA 14 168 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Affordable Care Act and What it Means for People with Disabilities Apply for NCD0114 Funding Number: NCD0114 Agency: National Council on Disability Category: Health Funding Amount: $135,000 |
| Fetal Alcohol Spectrum Disorders Practice and Implementation Centers Apply for CDC RFA DD14 1402 Funding Number: CDC RFA DD14 1402 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $275,000 |
| Improving Fetal Alcohol Spectrum Disorders Prevention and Practice through National Partnerships Apply for CDC RFA DD14 1403 Funding Number: CDC RFA DD14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| COMPREHENSIVE COMMUNITY HIV PREVENTION PROJECT FOR KEY AND VULNERABLE POPULATIONS (CP2) Apply for RFI CP2 TANZANIA Funding Number: RFI CP2 TANZANIA Agency: Agency for International Development Category: Health Funding Amount: $74,999,999 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 14 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.